FASLODEX® (fulvestrant) Injection for intramuscular administration is an estrogen receptor antagonist without known agonist effects. The chemical name is 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol.
FASLODEX is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Media Articles Related to Faslodex (Fulvestrant)
HER2-Positive Metastatic Breast Cancer: New Standard of Care
Source: Medscape Hematology-Oncology Headlines [2015.02.20]
Combining two targeted agents, trastuzumab and pertuzumab, with docetaxel resulted in unprecedented survival in HER2-positive metastatic breast cancer.
Medscape Medical News
Too Few Breast Cancer Patients Getting Radiation After Mastectomy: Study
Source: MedicineNet Chemotherapy Specialty [2015.02.18]
Title: Too Few Breast Cancer Patients Getting Radiation After Mastectomy: Study
Category: Health News
Created: 2/17/2015 12:00:00 AM
Last Editorial Review: 2/18/2015 12:00:00 AM
Estimates of gastric, breast cancer risk in carriers of CDH1 gene mutations
Source: Breast Cancer News From Medical News Today [2015.02.16]
More precise estimates of age-associated risks of gastric and breast cancer were derived for carriers of the CDH1 gene mutation, a cancer predisposing gene that is abnormal in families meeting...
Previously unknown genomic regions found in African American families with breast cancer
Source: Breast Cancer News From Medical News Today [2015.02.12]
Supports hypothesis that there may be genetic breast cancers specific to that populationThe "Jewels in our Genes" study, led by University at Buffalo researcher Heather Ochs-Balcom, has uncovered...
Many mastectomy patients with locally advanced breast cancer do not get postop radiation
Source: Breast Cancer News From Medical News Today [2015.02.11]
Journal of the American College of Surgeons study finds this gap in the standard of care is unrelated to socioeconomic factorsBreast cancer patients who undergo a mastectomy should receive...
Published Studies Related to Faslodex (Fulvestrant)
Ganitumab with either exemestane or fulvestrant for postmenopausal women with
advanced, hormone-receptor-positive breast cancer: a randomised, controlled,
double-blind, phase 2 trial. 
hormone-receptor-positive breast cancer... INTERPRETATION: Addition of ganitumab to endocrine treatment in women with
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. [2011.01]
BACKGROUND AND PURPOSE: Fulvestrant, an oestrogen receptor (ER) antagonist with no known agonist effects, has shown activity in postmenopausal patients with ER-positive advanced breast cancer recurring or progressing following prior endocrine therapy. This double-blind, double-dummy, randomised phase III study (NCT00327769) was designed to compare the efficacy and safety of fulvestrant versus anastrozole in advanced breast cancer of Chinese postmenopausal women whose disease has progressed following prior endocrine treatment... CONCLUSIONS: These data demonstrate that fulvestrant 250 mg and anastrozole were similarly effective and well tolerated in the treatment of postmenopausal Chinese women with advanced breast cancer whose disease had progressed or recurred on prior endocrine treatment.
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast
cancer: results of a multicentre, double-blind, randomised phase III trial. 
whose disease has progressed following prior endocrine treatment... CONCLUSIONS: These data demonstrate that fulvestrant 250 mg and anastrozole were
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). [2010.12]
BACKGROUND: FINDER1 compared efficacy, tolerability and pharmacokinetics (PK) of three fulvestrant dose regimens in postmenopausal Japanese women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer recurring or progressing after prior endocrine therapy... CONCLUSION: Fulvestrant AD, LD and HD had similar efficacy and tolerability profiles in postmenopausal Japanese women with ER-positive advanced breast cancer.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. [2010.10.20]
PURPOSE: We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy... CONCLUSION: Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity, corresponding to a clinically meaningful improvement in benefit versus risk compared with fulvestrant 250 mg.
Clinical Trials Related to Faslodex (Fulvestrant)
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer [Completed]
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast
cancer treatment and assess the relationship between dose, exposure, degree of reduction in
tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. [Active, not recruiting]
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant
with the standard dose of 250 mg in postmenopausal women with estrogen receptor positive
advanced breast cancer who have failed on a previous endocrine treatment.
Faslodex and Herceptin, Alone and Combined [Recruiting]
The purpose of this study is to evaluate the the relative anti-tumor efficacy of combined Faslodex and Herceptin therapy as compared with that of Faslodex or Herceptin given alone for first-line treatment in patients with metastatic breast cancer.
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
(exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
Patients will be treated until disease progression or until the investigator has determined
that treatment is not in the best interest of the patient, whichever occurs first.
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor [Recruiting]
The purpose of this study is to find out what effect the combination of fulvestrant
(Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant
Reports of Suspected Faslodex (Fulvestrant) Side Effects
Injection Site Pain (21),
Back Pain (17),
Pain in Extremity (15),
Disease Progression (14),
Hot Flush (13), more >>